Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenetic pathway as a therapeutic target in renal cell carcinoma.
Bianconi M, Scartozzi M, Faloppi L, Bittoni A, Maccaroni E, Giampieri R, Del Prete M, Burattini L, Cascinu S. Bianconi M, et al. Among authors: burattini l. Anal Quant Cytol Histol. 2012 Feb;34(1):15-22. Anal Quant Cytol Histol. 2012. PMID: 22590815 Review.
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, Giampieri R, Maccaroni E, Nicoletti S, Burattini L, Minardi D, Muzzonigro G, Montironi R, Cascinu S. Scartozzi M, et al. Among authors: burattini l. Br J Cancer. 2013 Mar 19;108(5):1126-32. doi: 10.1038/bjc.2012.501. Epub 2012 Nov 29. Br J Cancer. 2013. PMID: 23511629 Free PMC article.
Progress of molecular targeted therapies for advanced renal cell carcinoma.
Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, Cascinu S, Muzzonigro G. Conti A, et al. Among authors: burattini l. Biomed Res Int. 2013;2013:419176. doi: 10.1155/2013/419176. Epub 2013 Sep 4. Biomed Res Int. 2013. PMID: 24093097 Free PMC article. Review.
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S. Santoni M, et al. Among authors: burattini l. Cancer Immunol Immunother. 2013 Dec;62(12):1757-68. doi: 10.1007/s00262-013-1487-6. Epub 2013 Oct 17. Cancer Immunol Immunother. 2013. PMID: 24132754 Free PMC article. Review.
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.
Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R, Cascinu S. Santoni M, et al. Among authors: burattini l. Cancer Metastasis Rev. 2014 Mar;33(1):321-31. doi: 10.1007/s10555-013-9453-5. Cancer Metastasis Rev. 2014. PMID: 24337954 Review.
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
Minardi D, Santoni M, Lucarini G, Mazzucchelli R, Burattini L, Conti A, Bianconi M, Scartozzi M, Milanese G, Primio RD, Montironi R, Cascinu S, Muzzonigro G. Minardi D, et al. Among authors: burattini l. Urol Oncol. 2015 Mar;33(3):113.e1-7. doi: 10.1016/j.urolonc.2014.06.014. Epub 2014 Jul 26. Urol Oncol. 2015. PMID: 25069421
175 results